Gaja Alternative Asset Management Regulatory Approval

Gaja Alternative Asset Management Investor Presentation: Key Takeaways

Q2 FY27 total income ₹65.5 Cr (+26% QoQ); PAT ₹64.7 Cr, boosted by ₹15 Cr tax reversal. H1 PAT ₹91.9 Cr (+48% YoY). Net worth ₹1,106 Cr, debt-free.

Gaja Alternative Asset Management Dividend

Gaja AAM declared a first interim dividend of Rs. 0.50 per share on November 4, 2026. Record date for FY 27 dividend is November 12, 2026.

Gaja Alternative Asset Management Results Update

Gaja AMC reported Q2 FY27 total income of ₹117.3 Cr and H1 PAT of ₹91.9 Cr. Board declared ₹0.50 per share interim dividend.

Gaja Alternative Asset Management Q2 FY27 Results: Net Profit ₹64.7 Cr, Up 54.0% YoY

Gaja Alternative Asset Management Ltd reported revenue from operations of ₹38.4 Cr (-43.9% YoY) and net profit of ₹64.7 Cr (+54.0% YoY) for Q2 FY27.

Key figure

Net profit ₹64.7 Cr · +54.0% YoY

Gaja Alternative Asset Management Board Meeting Date

Gaja Alternative Asset Management will hold a board meeting on November 4, 2026 to consider Q2/H1 unaudited results and interim dividend. This is an advance intimation with no outcome yet.

Gaja Alternative Asset Management ED Probe / Tax Survey

Gaja Alternative Asset Management disclosed that the Punjab and Haryana High Court dismissed petitions to quash an FIR involving its MD and a fund director. The company says the order has no material financial impact.

John Cockerill India Regulatory Approval

John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.

Gland Pharma Regulatory Approval

Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.

City Union Bank Regulatory Approval

City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.

Execution

Three years from the date of taking charge

Lupin Regulatory Approval

Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.

Som Distilleries & Breweries Regulatory Approval

Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.

AGI Infra Regulatory Approval

Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.

Execution

Valid up to March 30, 2031